SCHEMBL6087004

SCHEMBL6087004

NC(=O)c1cc2ccc(OCc3ccccc3)cc2[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.66
SRD5A2 P31213 2/20 0.64
ALDH1A1 P00352 2/20 0.64
HPGD P15428 2/20 0.64
KDM4E B2RXH2 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2C9 P11712 1/20 0.64
HSD17B10 Q99714 1/20 0.64
CFD P00746 1/20 0.64
PDGFRB P09619 1/20 0.64
PDGFRA P16234 1/20 0.64
PARP10 Q53GL7 1/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
RXFP1 Q9HBX9 1/20 0.52
ALOX5 P09917 1/20 0.51
ACHE P22303 1/20 0.51
MAOB P27338 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089719 0.90 KDM4E (0.81) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL3030893 0.89 SRD5A2 (0.80) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL30920873 0.89 SRD5A2 (0.80) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL8406972 0.85 FLT3 (0.70) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL3057182 0.83 FLT3 (0.64) FLT3SRD5A2ALDH1A1HPGDKDM4E
Hydrochloric Acid SCHEMBL7877487 0.82 FLT3 (0.58) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL10002831 0.82 FLT3 (0.60) FLT3SRD5A2ALDH1A1HPGDKDM4E
Hydrochloric Acid SCHEMBL7877491 0.81 FLT3 (0.57) FLT3SRD5A2ALDH1A1HPGDKDM4E
SCHEMBL30909089 0.81 PDGFRB (0.58) FLT3ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL9949523 0.79 FLT3 (0.57) FLT3SRD5A2ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7125906-B2 Indole derivatives having anti-angiogenetic activity ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization ASTRAZENECA AB (SE) 2005-07-21 US disclosed
EP-1515716-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY Astrazeneca AB (SE) 2005-03-23 EP disclosed
WO-2003082271-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY ASTRAZENECA AB (SE) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization FLT1, FLT4, VEGFA FLT3 84/4885SRD5A2 1504/4885ALDH1A1 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.